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Adenoid cystic carcinoma (ACC) is an aggressive malignant neoplasm of the salivary glands in which c-Kit is
overexpressed and activated, although the mechanism for this is as yet unclear. We analyzed 27 sporadic ACC
tumor specimens to examine the biologic and clinical significance of c-Kit activation. Mutational analysis revealed
expression of wild-type c-Kit in all, eliminating gene mutation as a cause of activation. Because stem cell factor
(SCF) is c-Kit's sole ligand, we analyzed its expression in the tumor cells and their environment.
Immunohistochemistry revealed its presence in c-Kit–positive tumor cells, suggesting an activation of autocrine
signaling. We observed a significant induction of ERK1/2 in the cells. SCF staining was also found in other types of
non-cancerous cells adjacent to tumors within salivary glands, including stromal fibroblasts, neutrophils,
peripheral nerve, skeletal muscle, vascular endothelial cells, mucous acinar cells, and intercalated ducts.
Quantitative PCR showed that the top quartile of c-Kit mRNA expression distinguished ACCs from normal salivary
tissues and was cross-correlated with short-term poor prognosis. Expression levels of SCF and c-Kit were highly
correlated in the cases with perineural invasion. These observations suggest that c-Kit is potentially activated by
receptor dimerization upon stimulation by SCF in ACC, and that the highest quartile of c-Kit mRNA expression
could be a predictor of poor prognosis. Our findings may support an avenue for c-Kit-targeted therapy to improve
disease control in ACC patients harboring the top quartile of c-Kit mRNA expression.
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Adenoid cystic carcinoma (ACC) is the second most common
malignant salivary gland tumor [1–3]. It arises in the major and minor
salivary glands, as well as in the seromucinous glands of the upper
respiratory tract, and can also occur in other bodily sites with exocrine
glands, including the breast and lung. It is biphasic, composed of
duct-type epithelial cells and myoepithelial cells, and forms three
distinctive microscopic patterns that are categorized as predominantly
tubular, cribriform, or solid. Among these three histologic subtypes,
the solid form tends to have the highest recurrence rate and the worst
long-term prognosis.
ACC grows slowly with extensive local spread. Perineural invasion
along small and large nerves is common and often leads to pain,
numbness, and paralysis. In the head and neck, ACC often spreadsinto vital structures, including the brain. Although short-term survival
is high, almost half of all patients develop metastases or die of
complications of local recurrences within 10–20 years of diagnosis.
538 SCF activates c-Kit in salivary tumors Phuchareon et al. Translational Oncology Vol. 7, No. 5, 2014Even patients who achieve local tumor control can develop distant
metastases ten or more years after initial therapy. Thus, ACC is
considered to be a systemic disease with an unpredictable, unrelenting
course. Unfortunately, surgery, chemotherapy, and radiation therapy
provide little improvement in survival. Thus, an effective therapy is
urgently needed [3–5]. Possible molecular targets include the
transmembrane receptor tyrosine kinases (RTKs).
c-Kit (also known as CD117) is an RTK encoded by the KIT gene
[6]. Recent studies have demonstrated that overexpression of c-Kit
occurs in almost all ACCs [3–5,7,8]. In contrast, c-Kit expression is
seldom increased in other head and neck tumors. For this reason, c-Kit
expression is often used as a diagnostic pathology aid for ACC.
Furthermore, an analysis of protein phosphorylation of primary ACC
tumors recently showed that c-Kit was phosphorylated and activated
[9], although the mechanism underlying this activation remains unclear
[3,5]. Chromosome copy number gains at theKIT loci have been found
in only a small subset of ACC tumors [10], and the majority of ACCs
express wild-type c-Kit [11], although we recently found inactivating
c-Kit mutations in 2 of 17 ACC cases [3].
Given that c-Kit mutations in ACC are rare, c-Kit is likely to be
activated by receptor dimerization upon stimulation by stem cell factor
(SCF), its sole ligand [6]. SCF mRNA has been shown to be present in
tumor and normal salivary tissues [9]. Once c-Kit is activated, diverse
intracellular responses are induced through signaling cascades such as
the phosphoinositide-3 kinase and mitogen-activated protein kinase
pathways. This process contributes to numerous phenomena [6]. For
example, c-Kit activation is important for a variety of normal
physiologic processes, including hematopoiesis, spermatogenesis, and
the growth and migration of melanocytes [3,5,6].
A recent report found that c-Kit expression was correlated with poor
3-year outcomes in ACCs, while epidermal growth factor receptor
(EGFR) expression was correlated with a better 3-year outcome [12].
This finding warrants investigation of c-Kit inhibitors for potential
therapeutic use. However, the data regarding the impact of c-Kit
inhibition on ACC are conflicting. Two recent case reports suggested
that imatinib mesylate (Gleevec) inhibits the growth of ACC [13,14]. In
contrast, a Phase II clinical trial with the same drug induced no
significant response in 27 patients with ACC, despite high c-Kit
expression levels in their tumors [15]. These results suggest that reducing
c-Kit activity may not be sufficient to inhibit ACC's progression.
Nonetheless, c-Kit may play a key role in local invasion and distant
metastasis by accelerating mobilization of tumor cells. In melanocytes,
constitutive activation of c-Kit signaling promotes cell migration, but
does not significantly contribute tomelanogenesis and proliferation [16].
The objective of this study was to determine the expression of SCF
in ACC tumor cells, and/or the tumor environment, and to
investigate the clinical and biologic significance of c-Kit activation.
We propose a potential role of SCF for c-Kit activation based on its
tissue distribution and cell type-specific expression in ACC.
Materials and Methods
Tumor Samples
We obtained 27 ACC tissue samples from the University of
California, San Francisco (UCSF), Anatomic Pathology archives. In
addition, representative normal salivary tissue samples were chosen
from five of the ACC patients: cases 2, 14, 16, 19, and 22 in Table.
Institutional review board approval was obtained and UCSF
guidelines for handling human tissue were followed. Slides werereviewed to determine tissue suitability for genomic analysis and gene
expression analysis and to determine the histologic tumor pattern
(tubular, cribriform, or solid).
Immunohistochemistry
To examine c-Kit, SCF, or active ERK1/2 protein expression in ACC
tumors, we performed immunohistochemistry (IHC) on unstained
sections with antibody-based staining kits for c-Kit (104D2; Dako,
Carpinteria, CA), SCF (C19H6; Cell Signaling Technology [CST],
Danvers, MA), Phospho-p44/42 ERK1/2 (D13.14.4E; CST), and a
rabbit isotype control (3900; CST). The staining procedure has been
described [3]. c-Kit, SCF, and P-ERK1/2 staining was visually estimated
by a head and neck pathologist (AvZ). Assessment included the
percentage of tumor cells staining positive and the intensity of staining on
a five-point scale from negative (0) to very strongly positive (4+).
Mutation Analysis
Genomic DNA from each case of ACC was isolated from formalin-
fixed paraffin-embedded (FFPE) tissue sections with a QIAampDNA
FFPE Tissue kit (Qiagen, Valencia, CA) [3]. DNA samples were
amplified by PCR with the primer sets listed below and proofreading
capability platinum Taq DNA polymerase (Life Technologies,
Carlsbad, CA). Direct sequencing of PCR products was performed at
the UCSF Genomics Core Facility with ABI BigDye v3.1 dye
terminator sequencing chemistry (Applied Biosystems, Carlsbad, CA),
an ABI PRISM 3730xl capillary DNA analyzer (Life Technologies,
Carlsbad, CA), and Mutation Surveyor v2.5 (SoftGenetics, State
College, PA). We used the following oligonucleotide primer sequences
for detecting the KIT gene:
5′-CAGATTCTGCCCTTTGAACTTG-3′ and 5′-AAAAAGC
CACATGGCTAGAAAAA-3′ (Exon 8; 392 bp);
5′-TAAAAGTATGCCACATCCCAAG-3′ and 5′-CATGGT
CAATGTTGGAATGAAC-3′ (Exon 9; 368 bp);
5′-TCCAGAGTGCTCTAATGAC-3′ and 5′-AGGTGGAA
CAAAACAAAGG-3′ (Exon 11; 292 bp);
5′-AAGATGCTCAAGCGTAAGTTC-3′ and 5′-AAGCAGTT
TATAATCTAGCATTGCC-3′ (Exon 13; 302 bp); and
5′-GTGAACATCATTCAAGGCGT-3′ and 5′-CCTTTGCAG
GACTGTCAAGCA- 3′ (Exon 17; 336 bp).
TaqMan Quantitative PCR Assay
Gene expression was analyzed in triplicate with TaqMan quantitative
PCR. Total RNA was isolated with RNAeasy kits (Qiagen, Valencia,
CA) from FFPE tumor tissue sections composed of at least 70% tumor
cells. cDNA from 500 ng of total RNA was synthesized with an RT
First Strand Kit (Life Technologies, Carlsbad, CA). cDNA (5 ng) was
mixedwith RTqPCRmastermixes, and aliquots were placed with gene-
specific primer sets.We used the following TaqMan assays (all from Life
Technologies): KIT (Hs00174029_m1), SCF (Hs00241497_m1), and
EGFR (Hs01076078_m1). Expression levels normalized to endoge-
nous GAPDH were determined by real-time PCR and analyzed at the
UCSFCore noted above. Statistical analyses were performed and graphs
made with Microsoft Office Excel and XL-Stat (Addinsoft, New York,
NY). Statistical comparisons between data sets were made with two-
tailed Student's t tests and Wilcoxon tests according to the
manufacturers' instructions, with P b .05 considered significant.
(Wilcoxon testing, a hypothesis assessment that compares survival
distributions in two samples, is more sensitive than log-rank testing
Table. Clinicopathologic Features of ACC Samples
Case Gender Age Tumor sites Histology c-Kit SCF P-ERK1/2
Positive luminal cells Staining intensity Positive tumor cells Staining intensity Positive tumor cells Staining intensity
1 † M 78 Base of tongue Solid + tubular 100% 3+ 100% 1+ 20% 2+
2 F 64 Mandibular mucosa Tubular + cribriform 100% 1-3+ 100% 1-2+ 2% 3+
3 M 46 Maxillary sinus Tubular + cribriform 100% 2-3+ 100% 1+ 50% 2-3+
4 M 42 Maxillary sinus Tubular 100% 2-3+ 60% 1-2+ 20% 2+
5 M 59 Maxillary sinus Tubular + cribriform 100% 1-3+ 100% 1-2+ 10% 2-3+
6 F 68 Maxillary sinus Tubular + cribriform 100% 3+ 80% 1+ 50% 2-3+
7 F 75 Maxillary sinus Solid + tubular 100% 2-3+ 50% 1-2+ 2% 2-3+
8 F 36 Maxillary sinus Solid + tubular 100% 3+ 100% 1+ 1% 3+
9 M 41 Maxillary sinus Tubular 100% 3+ 100% 1+ 40% 2-3+
10 F 42 Maxillary sinus Tubular 100% 3+ 100% 1-2+ 70% 2+
11 † F 64 Maxillary sinus Tubular + cribriform 100% 2-3+ 100% 1-2+ 85% 2-3+
12 F 66 Nasal cavity Solid + cribriform 100% 2-3+ 80% 1+ 20% 2 -3+
13 F 44 Nasopharynx Cribriform 100% 2-3+ 100% 1+ 50% 2+
14 F 91 Parotid gland Solid 100% 3+ 100% 1+ 0% 0
15 † F 44 Parotid gland Solid + tubular 100% 2-3+ 100% 1+ 10% 3+
16 † M 33 Parotid gland Tubular + solid 100% 3+ 100% 1-2+ 15% 2-3+
17 F 54 Parotid gland Tubular + solid 100% 3+ 10% 1+ 20% 2-3+
18 F 60 Parotid gland Solid + tubular 100% 3+ 80% 1+ 20% 2-3+
19 M 66 Sublingual gland Cribriform 100% 3+ 100% 1+ 30% 2-3+
20 F 73 Sublingual gland Cribriform + tubular 100% 2-3 + 40% 1+ 15% 2-3+
21 † M 78 Submandibular gland Tubular + cribriform 100% 3+ 100% 1-2+ 50% 2+
22 M 59 Submandibular gland Cribriform + tubular 100% 2-3+ 100% 1+ 20% 2-3+
23 † M 54 Submandibular gland Tubular 100% 3+ 100% 1+ 30% 2-3+
24 F 44 Submandibular gland Cribriform + tubular 100% 2-3+ 90% 1-3+ 2% 3+
25 † F 51 Submandibular gland Cribriform + tubular 100% 2-3+ 90% 1-2 + 55% 3+
26 † F 70 Submandibular gland Tubular + solid 100% 2-3+ 100% 1+ 35% 3+
27 M 68 Tongue Cribriform 95% 1-3+ 20% 2+ 0% 0
Control normal salivary tissues were chosen from cases 2, 14, 16, 19 and 22.
† Perineural invasion was found in cases 1, 11, 15, 16, 21, 23, 25 and 26.
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times). Kaplan-Meier plots were generated and patients were divided
into groups on the basis of gene expression.
Statistical Power Analysis
Statistical power analysis for determining the sample size effective for
the result was performed by using Time to an Event, a sample-size
calculator (http://hedwig.mgh.harvard.edu/ sample_size/time_to_event/
para_time.html). All statistical tests were two-sided and conducted at
the .05 significance level.
Median survival was defined as the time after which 50% of
patients with ACC were living. The median survival ratio (N1) was
calculated by dividing one group's smallest median survival time by
the other group's smallest median survival time.Results
Tumor Characteristics
Table summarizes the clinical attributes of the patients in whom the
27 ACC tumor samples were obtained. All tumors had arisen
sporadically; 16 occurred in women; and themedian age at presentation
was 58 years (range, 33 to 91 years). Tumors arose at the following sites:
maxillary sinus (9 tumors), submandibular gland (6 tumors) or (6),
parotid gland (5 tumors) or (5), sublingual gland (2 tumors) or (2), and
one each in the nasal cavity, mandibular mucosa, nasopharynx, base of
tongue, and tongue. Tumors were classified by morphologic subtype:
tubular (4 tumors) or (4), cribriform (3 tumors) or (3), solid (1 tumor)
or (1), combined cribriform and tubular (10 tumors) or (10), combined
solid and tubular (8 tumors) or (8), and combined cribriform and
solid (1 tumor) or (1).Expression of c-Kit Protein is Elevated in Sporadic
ACC Tumors
We performed hematoxylin and eosin (H&E) staining
(Figure 1A) and antibody-based IHC for c-Kit on tumor sample
sections (Figure 1B [case 17] and Supplemental Figures 1B [case 2]
and 1F [case 7]). Mast cell staining was a positive internal control
with the antibody (data not shown). c-Kit staining was estimated as
described in Methods, and Table shows our results. c-Kit expression
occurred in the inner luminal (duct-type epithelial) cells of all the
tumors (see Figure 1B and Supplemental Figure 1B and F), as
reported previously [3].
Sequencing of KIT Gene Exons in the 27 ACC Tumors
In searching for genomic alterations, we examined exons 8, 9, 11, 13,
and 17, which encode domains for dimerization (exons 8 and 9), the
juxtamembrane region (exon 11), and protein kinase activity (exons 13
and 17). We chose them for this study because gain-of-function
mutations are recurrently found in these regions in other neoplasms [6].
We performed direct sequencing of each exon's PCR product. Each
sample was confirmed by at least three different sets of mutation
analyses. No missense, frameshift, nonsense, synonymous missense, or
splice mutations were detected.
SCF Expression in ACC Cells and Other non-Cancerous Cells
Adjacent to Tumors Within the Salivary Glands
In light of the results of our mutational analysis, we hypothesized
that c-Kit was activated by receptor dimerization upon stimulation by
SCF and used IHC to determine levels of SCF protein in the salivary
glands in tumor sample sections (Figure 1, C and D [case 17] and
Supplemental Figure 1C [case 2] and 1G [case 7]. SCF is present not
only as a secreted protein but also in membrane-bound form [6],
Figure 1. Expression of c-Kit, SCF, and P-ERK1/2 in ACC of the salivary glands. (A) H&E staining. (B)–(F). Immunohistochemistry with
antibodies to c-Kit (B), SCF (C and D), phospho-p44/42 ERK1/2 (E); antibody isotype control (F). SCF staining was largely in the duct-type
epithelial component in the tumors (C and D; indicated by black arrows) where c-Kit was predominantly elevated (B). We observed a
significant induction of ERK1/2 activity in the cells (E; black arrows). The staining intensity scales are as follows; c-Kit (B: 2-3+), SCF (C and
D: 1+), and P-ERK1/2 (E: 2+).
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distinction. Table summarizes our results. The vast majority of the
tumors expressed SCF (Figure 1B and Supplemental Figure 1B and F);
it was largely found in the duct-type epithelial component (Figure 1C)
where c-Kit was predominantly elevated (Figure 1B).
We used antibody-based IHC to detect active forms of ERK1/2
on tumor sections (Figure 1E). The Ras-Raf-MEK1/2-ERK1/2 cascade
is a major downstream effector-signaling pathway of RTKs, including
c-Kit. Thus, SCF-induced activation of c-Kit would accompany active
ERK1/2 expression in the inner duct-type epithelial component of the
tumor cells where c-Kit was elevated. Table summarizes our results. In
17 of 27 ACCs, active ERK1/2 protein was substantially increased in
more than 20% of tumor cells.
Interestingly, other types of non-cancerous cells adjacent to
tumors within salivary glands were positive for SCF. They included
stromal fibroblasts (Figure 2A and Supplemental Figure 2A and B),
neutrophils (Figure 2B and Supplemental Figure 2C and D),
peripheral nerve (Figure 2, C–E and Supplemental Figure 2E),skeletal muscle (Figure 2F and Supplemental Figure 2F), vascular
endothelial cells (Figure 2G), and mucous acinar cells and intercalated
ducts (Figure 2H). Strong immunoreactivity to the SCF antibody was
found in neutrophils and peripheral nerve (Figure 2, B and D). In
addition, Figure 2E shows that staining for SCF highlights a
peripheral nerve with a tumor wrapping around the nerve bundle,
creating a targetoid pattern.The Top Quartile of c-Kit mRNA Expression Distinguishes
ACCs from Normal Salivary Tissues
We investigated whether mRNA expression of c-Kit and SCF
was also elevated in ACC (Figure 3, A and B), and also included
EGFR because it has been implicated in the development of ACC
([17,18]; Figure 3C). mRNA was isolated from FFPE sections as
described above, and quantitative PCR performed. Figure 3A
shows that c-Kit mRNA expression was elevated in ACC, with the
relative expression increased by 1.88 (P b .05) over the average of
Figure 2. Immunohistochemical staining with antibodies to SCF in ACC cells and non-cancerous cells in the salivary glands (A-H).
(A) Stromal fibroblasts (black arrows). (B) Neutrophils around tumor (black arrows). (C) Nerve twigs (black arrows) and lymphocytes (red
arrows). (D) Tumor (black arrows) invading nerve (red arrows). (E) Targetoid pattern of tumor cells (black arrows) in perineural (red arrows)
invasion. (F) Skeletal muscle (black arrows) and tumor (red arrows). (G) Tumor (black arrows) and endothelial cells (red arrows) in blood
vessels. (H) Mucous acinar cells (black arrows) and intercalated ducts (red arrows).
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particularly distinguished ACCs from normal salivary tissues. In
contrast, the expression levels of SCF and EGFR mRNA showed
a broad range, which overlapped with those in normal tissue
(Figure 3, B and C) and showed no significant difference (P N .05)
from ACC samples.Expression Levels of SCF and c-Kit are Highly Correlated in
Cases With Perineural Invasion
Given that SCF-mediated c-Kit activity is important for local invasion
and metastasis, we determined the strength of correlation between SCF
and c-Kit mRNA expression in the presence (cases 1, 11, 15, 16, 21, 23,
25 and 26; Table) or absence of perineural invasion (PNI). We
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the median shown by a black horizontal line. The range and
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dots, respectively. The y-axis indicates the fold-change relative to
the average of normal samples' gene expression. Statistical
comparisons between data sets were performed with two-tailed
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All cases
Perineural invasion (+)
Perineural invasion (-)
SC
F 
m
RN
A 
(F
old
 ch
an
ge
)
c-Kit mRNA (Fold change)
0 1 2 3 4 5
1
2
3
y = -0.0859x + 0.7945 R² = 0.0099
6
SC
F 
m
RN
A 
(F
old
 ch
an
ge
)
c-Kit mRNA (Fold change)
0 1 2 3 4 5
1
2
3
y = 0.1418x + 0.5722 R² = 0.3811
6
y = 0.0685x + 0.5999 R² = 0.00139
SC
F 
m
RN
A
(F
old
 ch
an
ge
)
c-Kit mRNA (Fold change)
0 1 2 3 4 5
1
2
3
6
A
B
C
Figure 4. Expression levels of SCF and c-Kit in cases with
perineural invasion. (A)–(C) Scatter plot analysis for the strength
of a correlation between SCF and c-Kit mRNA expression in the
presence or absence of perineural invasion. (A) All cases. (B) Cases
with perineural invasion. (C) Cases without perineural invasion.
Trend lines are included. Trend line equations and R-squared
values were calculated separately.
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A–C). Trend line equations and R-squared values were calculated with
Microsoft Excel and are displayed atop each chart.
Expression levels of SCF and c-Kit were highly correlated in the 8
cases with PNI (Figure 4B); R-squared values (0 to 1 range) were
0.381 (R = 61.73%). In contrast, SCF and c-Kit expression
correlated poorly in the absence of PNI (Figure 4C; R-squared values
0.0099 [R = 9.94%]).The Highest Quartile of c-Kit mRNA Expression Predicts Poor
Prognosis in Salivary ACC Patients
To determine the biologic and prognostic significance of c-Kit, SCF,
and EGFRmRNA expression, we performed overall survival analysis by
generating Kaplan-Meier plots with Wilcoxon testing (Figure 5, A–D).
We divided our ACC cohort into 2 groups according to gene expression
scores (group 1: above the median; group 2: below it; Figure 5, A, C,
and E) and also created groups whose expression values were in the
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Figure 5. Kaplan-Meier curves showing overall survival rates of ACC patients according tomRNA expression of c-Kit (A and D), SCF (B and E),
or EGFR (C and F). The ACC cohort was divided into groups according to relative gene expression. Panels A to C compare patients with
expression in the top half overall (blue line) and the lower half (green line) for each gene. Panels D to F compare expression in the higher
quartile (blue line) and lower three quartiles (green line). Circles identify censored data. Statistical comparisons between data sets weremade
with Wilcoxon tests and each P value is displayed, with P b .05 considered significant.
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correlated with survival (Figure 5, A and D). Specifically, the subset
with the highest c-Kit gene expression (top quartile), which did not
overlap with the gene expression in normal tissue (Figure 3A), had the
poorest survival (P = .008).
To determine whether our sample size in the analysis provided
significance to this result, we performed a statistical power analysis as
described in Methods [19]. The total number of 27 cases
corresponded to a power of 0.87, providing confidence to this result,
where a power of ≥0.80 (equivalent to ≥22 total cases) is sufficient to
detect a large difference between two groups. In contrast, we did not
find a significant correlation between survival and expression of SCF
and EGFR (Figure 5, B, C, E, and F).
Discussion
c-Kit is overexpressed and phosphorylated in sporadic ACCs without
gene mutations [5]. The presence of SCF mRNA in tumor and
normal salivary tissue has been reported as a potential mechanism for
c-Kit activation in ACC [9]. However, it is not clear how SCF is
expressed or to what extent it contributes to c-Kit activation. Thegoal of this study was to characterize the pattern of SCF protein
expression in ACC tumor cells, and/or in the tumor environment,
and to examine the clinical and biologic significance of c-Kit
activation in ACC patients.
c-Kit is an oncogene [6]. Gain-of-function mutations in it occur in
a range of human cancers and are advantageous for tumor growth,
survival, and disease progression. For example, c-Kit mutations are
often found in mast cell leukemia and gastrointestinal stromal tumors
(GIST; 5, 6). However, gene mutations were not a cause of c-Kit
activation in our cohort of 27 ACCs studied here. Our results
confirmed studies from other laboratories [7,11].
We investigated whether ACC cells expressed c-Kit's ligand, SCF.
SCF was present not only in the tumor cells, which could mediate
autocrine signaling, but also in other types of cells adjacent to the
salivary glands. These cells might facilitate paracrine signaling [20]. In
particular, SCF expression was highest in nerve cells in the tumor
microenvironment. Peripheral nerves appear to release SCF into the
neural space, where it could act as a chemo-attractant and growth factor
critical for ACC. This observation may explain why ACC has a strong
tendency to infiltrate into neural structures and spread perineurally, and
544 SCF activates c-Kit in salivary tumors Phuchareon et al. Translational Oncology Vol. 7, No. 5, 2014why the tumor cells are frequently distributed around the nerve bundles
in a targetoid pattern. Moreover, we speculate that SCF may induce
c-Kit expression through a positive-feedback loop, a possibility
supported by our observation that expression levels of SCF and c-Kit
were highly correlated in the cases with perineural invasion. This finding
is in agreement with a recent report: c-Kit-negative PC3 prostate cancer
cells gained c-Kit expressionwhen the cells developedmetastasized bone
tumors in xenograft mice, where the bone marrow stromal cells
expressed SCF [21]. The study may offer a valuable clue about why
slow-growing ACCs become aggressive when the tumors invade the
neural space or metastasize to bone.
In this work, we performed phospho-ERK1/2 IHC simply as a way to
facilitate analysis. Our choice of this approachwas not intended to imply
that ERK1/2 is phosphorylated only by SCF-mediated c-Kit activation.
Moreover, the results were variable between cases likely owing to the
nature of antigenicity of phosphorylated protein. A recent study showed
that phosphorylated-ERK1/2 in primary tumors was largely degraded in
the process of formalin-fixation [22]. The extreme rarity of ACC limits
the fresh tissue donor pool. In addition, phospho-c-Kit IHCwith FFPE
samples is not yet established. Thus, in light of these limitations, we
believe that using phospho-ERK1/2 IHC with FFPE samples is the
most practical approach for accomplishing our purpose. There was a
substantial increase of active ERK1/2 protein inmore than 20%of ACC
tumor cells. We found that immunoreactivity was greater in the outer
myoepithelial cells than in the inner duct-type epithelial cells. The
difference could be attributed to the characteristic difference between
two cell types in ACC. c-Kit protein is specifically elevated in duct-type
epithelial cells, whereas EGFR expression is limited to the myoepithelial
cells [12]. Moreover, a differentiation marker p63 is predominantly
found in themyoepithelial but not duct-type epithelial component [23].
Thus, ERK1/2 activation appeared to be accelerated in differentiated
cells in ACC.
In this paper, we found that the highest quartile of c-Kit mRNA
expression was cross-correlated with short-term poor prognosis.
Because quantitative PCR is sensitive, reproducible and reliable for
determining the level of c-Kit mRNA, this gene expression analysis
may have a larger potential to identify the patients more likely to
benefit from c-Kit-targeted therapies in ACC [24,25]. These
therapies may include targeting c-Kit protein or upstream molecules
that regulate it.
It has been suggested that c-Kit is a downstream transcriptional target
of MYB, which is activated by gene fusion with nuclear factor nuclear
factor I/B (NFIB) in roughly half of ACC tumors [26,27]. However,
discrepancies in its cell-type-specific expression have led to questions
about the role of MYB for c-Kit transactivation in ACC. In recent
studies, MYB protein was elevated in myoepithelial cells, whereas c-Kit
expression was limited to the duct-type epithelial cells [12,28,29].
Further investigation is necessary, but c-Kit appears to be regulated by a
mechanism other than MYB activation in ACC tumors. As a
consequence, c-Kit may not be a useful biomarker to measure
response to MYB inhibitors in salivary tumors.
Imatinib is used to treat GISTs, which harbor oncogenic c-Kit [6].
The initial response to the drug is usually dramatic. Unfortunately,
most GISTs develop secondary KIT mutations during treatment,
resulting in drug resistance and subsequent recurrence. Nonetheless,
when imatinib is used as an adjuvant after surgical resection of
localized primary GISTs, the treatment offers long-term survival and
may result in a cure [30]. A similar adjuvant-based approach may
improve outcomes for a subset of ACC patients bearing the topquartile of c-Kit mRNA expression, and antibody-based c-Kit
targeted therapies could be also applicable [31,32].
In summary, c-Kit was shown to be potentially activated by
receptor dimerization upon stimulation by SCF in ACC. We
determined the pattern of SCF expression in the tumor cells and
other types of non-cancerous cells in salivary glands. We also showed
that the highest quartile of c-Kit mRNA expression distinguished
ACCs from normal salivary tissues and was a potential biomarker to
predict short-term poor prognosis in ACC patients. Given that there
are no validated ACC cell lines that have not been immortalized,
development of authenticated ACC cell lines is an important next
step to substantiate further the clinical usefulness of our findings
here [2].
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.07.006.
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